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Abstract 
Mutations of the TMPRSS6 gene, which encodes Matriptase-2, are responsible for Iron 
Refractory Iron-Deficiency Anemia. Matriptase-2 is a transmembrane protease that down-
regulates hepcidin expression. We report one frameshift (p.Ala605ProfsX8) and four novel 
missense mutations (p.Glu114Lys, p.Leu235Pro, p.Tyr418Cys, p.Pro765Ala) found in IRIDA 
patients. These mutations lead to changes in both the catalytic and non-catalytic domains of 
Matriptase-2. Analyses of the mutant proteins revealed a reduction of autoactivating cleavage 
and the loss of N-Boc-Gln-Ala-Arg-p-nitroanilide hydrolysis. This resulted either from a direct 
modification of the active site or from the lack of the autocatalytic cleavage that transforms the 
zymogen into an active protease. In a previously described transfection assay measuring the 
ability of Matriptase-2 to repress the hepcidin gene (HAMP) promoter, all mutants retained 
some, if not all, of their transcriptional repression activity. This suggests that caution is called for 
in interpreting the repression assay in assessing the functional relevance of Matriptase-2 
substitutions. We propose that Matriptase-2 activity should be measured directly in the cell 
medium of transfected cells using the chromogenic substrate. This simple test can be used to 
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determine whether a sequence variation leading to an amino acid substitution is functionally 
relevant or not. 
 
Key words: TMPRSS6, Matriptase-2, hepcidin, anemia, IRIDA 
 
 
Introduction 
Patients with Iron Refractory Iron Deficiency Anemia (IRIDA; MIM# 206200) absorb 
insufficient amounts of iron from the diet and respond inadequately to oral iron therapy. IRIDA 
is characterized by low serum iron, low serum ferritin, and high plasma levels of hepcidin, the 
master regulator of systemic iron homeostasis. This disease is caused by biallelic mutations of 
the TMPRSS6 gene (MIM# 609862) that encodes Matriptase-2 (MT2), a transmembrane serine 
protease of the type-two transmembrane serine protease (TTSP) family, which is mainly 
expressed in the liver. The role of MT2 in iron homeostasis was initially demonstrated by the 
discovery of a homozygous splice site mutation of Tmprss6 in the Mask mouse (Du, et al., 2008) 
followed by the characterization of the Tmprss6 knockout mice (Folgueras et al., 2008). These 
mice suffer from microcytic anemia due to reduced absorption of dietary iron caused by high 
levels of hepcidin. Hepcidin gene (HAMP) expression is mainly dependent upon Bone 
Morphogenetic Protein 6 (BMP6) and hemojuvelin (HJV). Binding of the BMP6 cytokine to its 
receptors activates a signaling cascade leading to HAMP transcription via phosphorylation of 
Son of Mother Against Decapentaplegic (SMAD) 1/5/8 effectors. HJV, a GPI-linked membrane 
protein synthesized by the hepatocytes, is a BMP6 coreceptor (Babitt, et al., 2006; Xia, et al., 
2008). The critical role of the BMP6/HJV/SMAD pathway in iron homeostasis is supported by 
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the loss of hepcidin expression and massive parenchymal iron overload observed in several 
mouse models, including mice in which BMP type I receptor genes (Alk2, Alk3) have been 
deleted in the liver (Steinbicker, et al., 2011), Bmp6-/- (Meynard, et al., 2009, Andriopoulos, et 
al., 2009) and Hjv-/- mice (Vaulont, et al., 2005) as well as in mice with targeted liver deletion of 
Smad4 (Wang, et al., 2005). Similar severe iron overload (juvenile hemochromatosis) is 
observed in patients with mutations in HFE2, which encodes for the HJV protein. On the basis of 
transfection experiments, it has been postulated that MT2 down-regulates hepcidin levels by 
binding to and proteolytically degrading the BMP co-receptor HJV (Silvestri, et al., 2008). 
However, recent experiments performed in vivo do not support this hypothesis. Indeed, Gibert et 
al showed that the increase in hepcidin expression that follows the knockdown of the Tmprss6 
gene in a zebrafish embryo is independent of HJV (Gibert, et al., 2011). Furthermore, Krijt et al 
showed that in Tmprss6-/- mice, the amount of membrane-bound HJV (mHJV) protein in liver 
was significantly reduced, and not increased as expected (Krijt, et al., 2011).  
From its N- to its C-terminus, MT2 is composed of a small cytoplasmic domain, a 
transmembrane domain, a stem region consisting of a SEA (sea urchin Sperm protein 
Enterokinase Agrin) domain, two CUB (C1s/C1r, Urchin embryonic growth factor and Bone 
morphogenetic protein) domains, three LDLRA (low-density lipoprotein receptor class A) 
domains, and a carboxy terminal serine protease (SP) domain (see Figure 1A). Three residues in 
the SP domain, Histidine 617, Aspartate 668 and Serine 762 (the catalytic triad) are essential for 
protease activity (Szabo and Bugge, 2011). Like other TTSPs, MT2 is synthesized as a zymogen 
that needs its own trypsin-like serine protease activity to become activated. Autoactivation of the 
zymogen is characterized by a cleavage after the Arginine 576 within a highly-conserved Arg-
Ile-Val-Gly-Gly (RIVGG) motif located at the junction between the SP domain and the stem 
UN
CO
RR
EC
TE
D 
AC
CE
PT
ED
 A
RT
IC
LE
 
 5
(Figure 1A). It has been shown that MT2 is activated via a transactivation mechanism involving 
multimerization of the zymogen (Stirnberg, et al., 2010) at the plasma membrane. Following 
activation, the SP domain remains bound to the stem by a disulfide bound. The active protease is 
released from the cell membrane into the extracellular medium by proteolytic cleavage within 
the stem (Stirnberg, et al., 2010). So far, 34 MT2 mutations have been identified in human 
patients with IRIDA (Altamura, et al., 2010; Beutler, et al., 2009; Choi, et al., 2011; De Falco, et 
al., 2010; Edison, et al., 2009; Finberg, et al., 2008; Guillem, et al., 2008; Melis, et al., 2008; 
Ramsay, et al., 2009b; Sato, et al., 2011; Silvestri, et al., 2009; Tchou, et al., 2009). These 
include missense, nonsense, frameshift, and splice junction mutations. Missense mutations have 
been found in several different protein domains of the extracellular part of the zymogen, and 
some of them have been further characterized by transfection experiments, usually by assessing 
the ability of mutated proteins to repress the hepcidin promoter linked to a luciferase reporter 
gene (Altamura, et al., 2010; De Falco, et al., 2010; Du, et al., 2008; Ramsay, et al., 2009b; 
Silvestri, et al., 2009; Silvestri, et al., 2008). Here we describe five mutations observed in IRIDA 
patients, one homozygous frameshift mutation, found in one family, and four missense mutations 
located in the CUB1, CUB2, SEA, and SP domains of MT2, found in two families with 
compound heterozygosity of the affected children. We studied the functional consequences of 
the mutations on the activation of the zymogen, the release of the protease activity into the 
medium of transfected cells and the repression of the hepcidin promoter. We also studied two 
designed mutant controls: p.Arg576Ala (R576A) and p.Ser762Ala (S762A). The (R576A) 
mutant was designed to prevent the autoactivation of MT2 by replacing the arginine that is 
targeted by the autocatalytic activating cleavage. The S762A mutant is a catalytically inactive 
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protein in which the serine residue directly involved in the proteolytic activity of the enzyme has 
been replaced by an alanine (Stirnberg, et al., 2010).  
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Materials and Methods 
Patients (see Table 1 and Figure 2) 
Family A: Two affected brothers were born to healthy, first-cousin parents from Algeria. The 
eldest brother received several courses of oral iron during his childhood. No hematological data 
were available from before he was diagnosed with microcytic anemia when he was 15 years old. 
At the time of diagnosis he had 7.3 g/dL hemoglobin, and a MCV of 54 fL. Since then, he had 
received several courses of intravenous iron, and when 25 years of age he had a normal 
hemoglobin level (12 g/dL), although the microcytosis persisted. His serum ferritin had risen 
from 6 μg/L (when 15 years of age) to 230 μg/L (when 25 years of age). His younger brother 
was noted by his parents to display pallor at birth. He was diagnosed with microcytic anemia 
when he was 1 year old (Hb: 7.4 g/dL and MCV: 51 fL). Intravenous (IV) iron was administered 
from the age of 8 years, and he responded well, with 12 g/dL of hemoglobin and an MCV of 64 
fL at the age of 17 years.  
Family B: Two affected brothers were born to non-consanguineous parents of French origin. 
Both patients presented with microcytic hypochromic anemia at 4 years and 6 months of age, 
respectively. Occult gastrointestinal blood loss and gluten enteropathy were excluded. 
Hematological and bone marrow examinations ruled out other possible causes of anemia. With 
oral iron treatment, both patients reached an acceptable hemoglobin level (11 g/dL), but 
remained microcytic with low serum iron, normal total iron binding capacity (TIBC), and very 
low transferrin saturation. Both of them displayed a decrease in hemoglobin concentration when 
iron supplementation was discontinued.  
Family C: The patient was a French boy born to non-consanguineous parents. He was diagnosed 
with hypochromic microcytic anemia when he was 3 years old, and was given oral iron 
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continuously for 17 months. His hemoglobin concentration progressively rose to 12 g/dL, but 
then fell back to 10.5 g/dL when the treatment was discontinued. A year and a half later he was 
given a single dose of intravenous iron. This was followed by an increase in hemoglobin 
concentration that persisted for 2 years. He was then given oral iron supplementation again. 
Serum hepcidin concentrations were measured by ELISA (Intrinsic Life Sciences, USA) and are 
shown in Table 1. 
Blood samples for genetic analysis were obtained from the patients or their parents after they had 
signed informed consent forms in accordance with the requirements of the French Bioethics 
legislation. 
 
TMPRSS6 sequencing and DNA constructs 
Exons and intron-exon junctions of the TMPRSS6 gene were sequenced as previously described 
(Guillem, et al., 2008) and compared to the reference sequence NM_153609.2 (GenBank). 
Mutant alleles are named according to journal guidelines (www.hgvs.org) and have been 
submitted to the Leiden Open Variation Database (http://www.lovd.nl/TMPRSS6). The full-
length human MT2 cDNA with a C-terminal FLAG epitope cloned in the pcDNA3.1 vector was 
kindly provided by Carlos Lopez Otin. Expressing vectors encoding MT2 mutants found in 
IRIDA patients: p.Glu114Lys (E114K), p.Leu235Pro (L235P), p.Tyr418Cys (Y418C), 
p.Pro765Ala (P765A), p.Ala605Pro+8fsX (A605fs), and designed mutants Arg576Ala (R576A) 
and Ser762Ala (S762A), were obtained by mutagenesis of wild-type cDNA using a Quickchange 
site-directed mutagenesis kit (Stratagene), sequences of the oligonucleotides are available upon 
request. To generate MT2-V5 expressing vectors, pcDNA wild type (WT) MT2-FLAG was 
digested using BsteII and XhoI enzymes, and the digested plasmid was purified on agarose gel 
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and dephosphorylated. An insert containing a V5 tag was made by hybridizing two 
oligonucleotides phosphorylated at their 5’ extremity (sequences are available upon request), and 
ligation into the previously digested plasmid. In order to introduce the FLAG sequence in front 
of the stop codon of the A605fs mutant, we used four primers for Site Directed, Ligase-
Independent Mutagenesis (SLIM) according to Chiu et al. protocol (Chiu, et al., 2004): PCR was 
performed with the four primers Rt 5’cccagcggtcagcgatgagggccccccacagatgtgtcg3’, Rs 
5’gggccccccacagatgtgtcg3’, Fs 5’gactacaaggacgacgatgac3’, Ft 
5’tcatcgctgaccgctggggactacaaggacgacgatgac3’ with pcDNA3 WT MT2 as a DNA template. To 
generate the pcDNA WT HJV construct, the full human ORF was amplified from human liver 
cDNA and inserted into pcDNA3 using TOPO cloning (Invitrogen). The whole cDNA sequence 
of each construct was verified by sequencing after mutagenesis.  
 
 
Cell culture 
HeLa and Huh7 cells were cultured at 37°C in Dulbecco’s modified Eagle’s Medium (DMEM) 
with L-glutamine and 1 g/L glucose, supplemented with antibiotics (penicillin, streptomycin), 
and 10% heat decomplemented fetal bovine serum, in 95% humidified air and 5% CO2. 
 
Western blots on cell lysates and concentrated media  
HeLa and Huh7 cells seeded in 10-cm diameter dishes and grown up to 50-70% confluence were 
transiently transfected with Fugene HD reagent (Roche) in optiMEM according to the 
Manufacturer’s instructions. After 24 h, the medium was replaced with 4.5 mL of fresh 
optiMEM with antibiotics. The medium was collected 24h later, and concentrated using 10-kDa 
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molecular weight cutoff ultrafiltration membranes (Amicon ultra, Millipore). Cells were lysed in 
lysis buffer (Cell Signaling Technology) supplemented with an antiprotease cocktail (Roche). 
Forty μg of proteins in denaturing and reducing Laemmli buffer were loaded per well of 10% or 
12% polyacrylamide gel for cell lysates (CL) and concentrated media (CM), respectively. 
Proteins were transferred onto an Immobilon-P transfer membrane (Millipore), using an 
Invitrogen electrophoresis system. After blotting, membranes were blocked overnight at 4°C in 
7% milk diluted in TBS-Tween (0.15%). Membranes were incubated with a mouse anti-FLAG 
M2 monoclonal antibody (Sigma) diluted 1/10000 (CL) or 1/5000 (CM), and then with a sheep 
secondary anti-mouse antibody diluted 1/3000 (Amersham Bioscience). Anti-actin primary 
antibody (Sigma) and anti-mouse secondary antibody (Amersham Bioscience) were used at 
1/7500 dilution. All the antibodies were incubated for one hour (with the exception of actin: 
30 min) at room temperature. Immunoblots were visualized by chemiluminescence using the 
HRP (horseradish peroxidase) substrate (Millipore).  
 
Immunofluorescence 
Huh7 cells grown to 50-70% confluence on a glass coverslip 1.8 cm in diameter were transiently 
transfected with pcDNA WT MT2 or with constructs expressing the missense mutants. The 
transfection medium was replaced after 24h with fresh optiMEM, and immunofluorescence 
labeling was performed 24h later. The dilution of primary rabbit polyclonal anti-FLAG antibody 
(Sigma) was 1/250, and the dilution of the anti-rabbit secondary antibody labeled with FITC 
(Invitrogen) was 1/200. 
 
Luciferase assay 
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Huh7 cells seeded at 50-70% confluence in a 24-well plate were transiently transfected with TK 
Renilla plasmid encoding Renilla reniformis luciferase, and with a construction containing the 
Photinus pyralis luciferase gene controlled by the HAMP gene promoter (Patel, et al., 2012). 
Cells were also co-transfected with the pcDNA HJV-expressing vector and WT or mutated MT2 
expressing plasmid, in optiMEM. After 48h, the cells were lysed with passive lysis buffer 
(Promega), and the luciferase activity was determined according to the Manufacturer’s 
instructions (Dual glo luciferase reporter assay, Promega). The relative luciferase activity was 
determined as the ratio of the HAMP promoter Photinus pyralis firefly to Renilla reniformis 
luciferase activity. Experiments were performed in triplicate. 
 
Measurement of MT2 proteolytic activity  
Hela cells were transfected with either WT or mutant MT2-expressing constructs as described 
above. After 24 hours, 50μg of proteins from concentrated media were used to measure the 
protease activity by monitoring the release of p-nitroanilide from the chromogenic substrate N- 
(tert-butoxycarbonyl)-Gln-Ala-Arg-p-nitroanilide (400 μM) at a wavelength of 405 nm during an 
incubation of 20 minutes in Tris/Saline buffer (50 mM Tris, 150 mM NaCl, pH8.0) at 37°C.  
 
Co-Immunoprecipitation assay 
Cell lysates obtained as described for the Western blots were incubated with 2 μg of anti-V5 
monoclonal antibodies (Invitrogen) or anti-FLAG monoclonal antibodies for one hour at 4°C. 
BioAdem beads PAG (protein A and G) diluted in lysis buffer were added to the immune 
complexes and incubated overnight at 4°C while stirring. After washing three times with lysis 
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buffer, proteins bound to antibodies were eluted with PAG elution buffer. This experiment was 
performed using Ademtech magnetic devices. 
 
Results 
We describe five patients with IRIDA belonging to three families (Table 1 and Figure 2). Two 
brothers in family A were diagnosed with typical features of IRIDA: microcytic anemia with low 
serum iron, high concentration of plasma hepcidin, no response to oral iron and only a partial 
response to intravenous iron therapy. In contrast, in the other two families, the patients (two 
brothers in family B and a single affected child in family C), had an unusual clinical history since 
they had responded partially to sustained oral iron therapy. Otherwise, they also showed typical 
symptoms of IRIDA with persisting microcytosis under therapy. Their plasma hepcidin level was 
in the normal range though abnormally high when their hemoglobin concentration was taken into 
account (Ganz, et al., 2008). However, it should be noted that patients from both these families 
would have been considered to be unresponsive to oral iron according to the usual criteria, since 
only long-lasting and sustained oral iron therapy was able to maintain even a subnormal 
hemoglobin concentration, and the hemoglobin level fell when oral iron was discontinued.  
We identified four novel and one previously described mutations of the TMPRSS6 gene in the 
three families (Figure 2). In family A, a previously reported mutation (Finberg, et al., 2008) was 
found in the homozygous state in the two brothers born to consanguineous parents, and consisted 
of a single nucleotide deletion: c.1813delG; p.Ala605ProfsX8 (A605fs). This mutation was 
predicted to lead either to RNA degradation or to a truncated protein. In family B, the affected 
brothers were heterozygous for two missense mutations, c.704T>C; p.Leu235Pro (L235P) in the 
CUB domain 1 and c.1253A>G; p.Tyr418Cys (Y418C) in the CUB domain 2. The father and the 
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mother were heterozygous for the L235P mutation and the Y418C mutation, respectively. In 
family C, the proband was heterozygous for two other missense mutations: c.340G>A; 
p.Glu114Lys (E114K) in the SEA domain and c.2293C>G; p.Pro765Ala (P765A) in the SP 
domain. The father and the mother were heterozygous for the P765A mutation and the E114K 
mutation, respectively. The location of the mutations in the different protein domains is shown 
on Figure 1A. All four amino acid substitutions affect evolutionarily conserved residues (Figure 
1B) and were predicted to be damaging by Polyphen2 software 
(http://genetics.bwh.harvard.edu/cgi-bin/pph2).  
 
MT2 missense mutant proteins are targeted to the plasma membrane 
In order to find out whether the missense mutations found in IRIDA patients modify the 
localization of the protein at the cell membrane, Huh7 cells were transiently transfected with the 
cDNA encoding the WT MT2 and each of the four missense IRIDA mutants with a FLAG-
epitope. In non-permeabilized cells, the MT2 mutants were detected at the membrane of Huh7 
cells, in a similar way to the WT protein (Supp. Figure S1).  
 
Repression of HJV-induced HAMP promoter activity by MT2 mutants 
To assess the impact of MT2 mutations on hepcidin gene activity, we transfected Huh7 cells with 
a HAMP promoter-Photinus luciferase reporter vector and a TK-Renilla luciferase vector to 
normalize transfection efficiency between samples. Cells were also co-transfected with the HJV-
expressing vector, and either WT or mutant MT2-expressing vectors. We tested the five IRIDA 
mutants plus two designed mutants as controls: R576A and S762A. WT MT2 repressed HJV-
induced luciferase activity 8 fold compared to HJV transfection alone (Figure 3). Surprisingly, 
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all the mutants repressed HAMP promoter-driven luciferase expression, and only some of them 
(Y418C, L235P, E114K and R576A) were significantly, although moderately, less efficient than 
WT MT2. The A605fs mutant displayed only weak repressor activity. We performed this 
experiment three times, and Figure 3 shows the results of one representative experiment. 
Repression of the hepcidin promoter was also demonstrated under conditions where HuH7 cells 
were transfected with MT2-expressing vectors in the absence of the HJV-expressing vector both 
under unstimulated conditions and in the presence of added BMP2 (Supp. Figure S2). This 
suggests that both the wild-type MT2 and the missense mutants are able to interfere with 
endogenous HJV when overexpressed in HuH7 cells. 
 
Autocleavage of MT2 mutants 
In order to determine the autocatalytic cleavage activity of MT2 mutants, HeLa cells were 
transfected with plasmid constructs expressing either WT MT2 or each of the MT2 mutants, or 
combinations of Y418C/L235P and E114K/P765A mutants. The corresponding proteins were 
detected in cell lysates (CL) with an apparent molecular weight of 120 kDA for both WT MT2 
and the missense mutants, corresponding to full length zymogens (Figure 4A, CL). As expected, 
the truncated mutant that lacks 198 amino acid residues was detected with an apparent molecular 
weight of 90 kDa (Figure 4A, CL). When the concentrated medium (CM) of HeLa cells 
transfected with WT MT2-FLAG cDNA was analyzed using sodium dodecyl sulfate (SDS) 
PolyAcrylamide Gel Electrophoresis (PAGE) under reducing conditions, the hallmark of the 
autoactivating cleavage of the zymogen was present, i.e. a 30-kDa fragment corresponding to the 
SP domain (Figure 4A, CM). As expected, the R576A mutant could not be processed at the 
RIVGG site, and the corresponding 30-kDa fragment was not detected in the cell medium. The 
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S762A mutant was not cleaved either, confirming that the catalytic activity of the MT2 zymogen 
itself is necessary for its activating cleavage to occur. Similarly, no 30-kDa fragment was 
observed for the Y418C, L235P, and E114K mutants, either alone or in combination while 
transfection of the P765A mutant resulted in a reduction of the intensity of the 30-kDa fragment 
compared to that found for WT MT2. For the A605fs mutant, which is completely devoid of the 
SP domain, no cleavage fragment was detected. 
In transfected Huh7 cells, no residual autocleavage was observed with any of the mutants studied 
(Figure 4B, CM). 
 
MT2 missense mutants are not trans-activated by wild-type protein 
Stirnberg, et al. demonstrated that a MT2 protein mutated in the catalytic serine S762A can be 
modified by trans-cleavage at the RIVGG site by its WT counterpart (Stirnberg, et al., 2010). We 
investigated whether the missense IRIDA variants could be processed in the same way. Huh7 
cells were co-transfected with a plasmid expressing either one of the FLAG-labeled mutants and 
the WT MT2 expressing construct with a V5 epitope. Full length MT2-V5 and the autoactivation 
fragment were detected with the anti-V5 antibody in the cell lysate and cell medium, respectively 
(Figure 5, CL and CM). When the S762A MT2-FLAG mutant was co-transfected with WT 
MT2-V5, a 30-kDa fragment was also detected with the anti-FLAG antibody by Western blot 
analysis under reducing conditions, in agreement with data previously reported (Stirnberg, et al., 
2010). In contrast, none of the four IRIDA mutants was cleaved by WT MT2. This may indicate 
a conformational defect that either prevents the formation of MT2 oligomers or modifies the 
accessibility of the RIVGG cleavage site. 
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MT2 IRIDA mutations do not alter protein-protein interactions 
Since IRIDA mutants were not transactivated by the WT MT2 protein in Huh7, we investigated 
whether this was a consequence of an impaired interaction between WT and the mutated 
proteins. HeLa cells were transfected with WT MT2-V5 in the presence of either WT or mutant 
MT2-FLAG. Cell lysates were immunoprecipitated either with anti-V5 or anti-FLAG antibodies, 
and the immunoprecipitates were analyzed by immunoblotting with anti-V5 and anti-FLAG 
antibodies (Supp. Figure S3). WT MT2-FLAG was detected in anti-V5 immunoprecipitate, and 
reciprocally WT MT2-V5 was present in anti-FLAG immunoprecipitate. All missense IRIDA 
MT2-FLAG mutated proteins co-immunoprecipitated with WT MT2-V5, which suggests that the 
defect in the transactivation of IRIDA variants by WT MT2 was not due to impaired interaction 
between the mutated and WT MT2 protein.  
 
Proteolytic activity in the media of cells transfected with WT and mutated-MT2 using a 
chromogenic substrate 
In order to assess the protease activity resulting from the shedding of MT2 into the culture 
medium of transfected Hela cells, proteolytic activity in concentrated medium from transfected 
cells were assayed, using a chromogenic substrate previously used in two different studies 
(Meynard, et al., 2011; Sisay, et al., 2010). None of the mutants tested showed any detectable 
protease activity, whereas absorbance increased linearly with incubation time in the WT MT2 
(Figure 6).   
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Discussion 
In this paper, we tested the functional consequences of four new missense mutations of 
TMPRSS6 gene identified in five IRIDA patients from three families. We used several different 
assays with two aims: firstly, to find out whether these novel variants were indeed causal 
mutations and, secondly, to try to further elucidate the functioning of MT2. We initially used a 
previously described transfection assay that measures the ability of MT2 mutants to repress the 
expression of a luciferase reporter gene driven by the HAMP promoter. One of the four IRIDA 
mutants (P765A) repressed HAMP-driven luciferase expression to a similar extent as the WT 
construct, and all the mutants tested still produced some degree of transcriptional repression 
activity, including the negative control S762A mutant in which the serine of the catalytic triad is 
replaced by an alanine. Although we found these observations surprising, a careful analysis of 
the literature shows that several missense mutants also have a repressive effect (Table 2). In one 
case, similar findings had in fact already been reported (Ramsay, et al., 2009b). In other papers, 
the focus was solely on the difference between mutants and WT MT2, and the residual repressive 
activity of the mutants had been overlooked (Altamura, et al., 2010; Du, et al., 2008; Ramsay, et 
al., 2009b; Silvestri, et al., 2009; Silvestri, et al., 2008).  
Since the catalytic activity of MT2 is considered to be essential for its function, we tested it in 
transfection experiments in two different types of cell: HeLa cells and the hepatocyte cell line 
Huh7. The IRIDA mutants, the inactive S762A mutant, and an additional mutant R567A all 
displayed a profound defect in protease activity as compared to the WT construct. This 
abnormality was revealed by a defective cleavage at the RIVGG sequence that links the SP 
domain to the stem. This cleavage is required for conversion of the inactive zymogen form of 
membrane MT2 into an active protease, and is catalyzed by a transactivation mechanism that 
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involves MT2 dimerization or oligomerization (Stirnberg, et al., 2010). This autocatalytic 
cleavage was severely impaired for all the mutants, except P765A, for which it was partially 
conserved in HeLa cells, and it was absent for all mutants in Huh7 cells. This observation 
suggests that this cleavage may somehow depend on the tissue-specific microenvironment of the 
protein. There was an absence of cleavage at the RIVGG sequence of the four IRIDA mutants by 
the WT MT2 in cotransfection experiments, whereas the control mutant, S762A, was cleaved by 
the WT MT2. This suggests that the four missense mutations studied here might induce a change 
in protein conformation that reduces the accessibility of their cleavage site.  
To evaluate the proteolytic activity in the culture medium from HeLa cells expressing MT2 
proteins with IRIDA mutations, we used a synthetic chromogenic substrate. Interestingly, none 
of the four missense mutants, either separately or in combination (Y418C/L235P and 
E114K/P765A), displayed any detectable proteolytic activity against the substrate in contrast to 
WT MT2. For the three mutants Y418C, L235P, and E114K, this finding was in agreement with 
the absence of MT2 SP domain released from the cell membrane. Surprisingly, the P765A 
mutant showed no activity either, despite a detectable amount of autoactivation fragments in the 
media (Figure 4A). Noteworthy, amino acids 750 to 810 in the MT2 protein are essential for 
serine protease function as this region constitutes the substrate binding site (Ramsay, et al., 
2009a). As a consequence, the P765A mutation might modify the affinity of the protease for the 
substrate, most likely explaining its defective serine protease activity when released into the cell 
culture medium.  
 
All previously published mutants for which the protease activity has been assessed and the four 
novel missense mutants reported here share a loss of catalytic activity, even though many of the 
UN
CO
RR
EC
TE
D 
AC
CE
PT
ED
 A
RT
IC
LE
 
 19
missense mutations do not target the SP domain. The inactivating mechanisms resulting from the 
mutations seem to be diverse, and may fall into different categories. In some cases the mutated 
protein is not targeted correctly to the plasma membrane and is retained in the endoplasmic 
reticulum or Golgi apparatus (Silvestri, et al., 2009). In other cases, the mutation directly 
modifies the active site of the protease (Silvestri, et al., 2008) and in several cases, the mutation 
prevents the activation of the zymogen into the active form of the enzyme without directly 
modifying the amino acid sequence of the SP domain. The reason for the repressive effect of 
many mutants with protease activity defects remains unclear, and is probably artifactual. These 
observations suggest that the findings from the repression assay used to assess the functional 
relevance of MT2 protein variants should be interpreted with caution and may be misleading. In 
practice, we suggest that SP activity in the cell medium of transfected cells should be measured 
directly using the chromogenic substrate. This is a simple in vitro test used to determine whether 
a sequence variation leading to an amino acid substitution is functionally relevant or not. 
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Figure legends  
Figure 1: Location of the mutations in the MT2 protein. 
A. Schematic representation of the MT2 domains and location of the various mutations studied. 
The autoactivating cleavage site in the consensus RIVGG sequence is indicated by an arrowhead.  
L= LDLRA domain, TM= transmembrane domain. 
B. MT2 protein sequences from different species were aligned using the blastp software from the 
NCBI server. Sequences were from the following GenBank entries: Homo sapiens: 
NP_998818.1, Canis lupus: XP_001154526.1, Mus musculus: XP_533038.2, Rattus norvegicus: 
UN
CO
RR
EC
TE
D 
AC
CE
PT
ED
 A
RT
IC
LE
 
 25
XP_589838.2, Gallus gallus: NP_081402.2. Amino acids mutated in IRIDA patients in this study 
are outlined. 
 
 
Figure 2: Family pedigree of the IRIDA patients and TMPRSS6 genotypes.  
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Figure 3: Repression of the HAMP promoter by MT2 variants. 
Huh7 cells were transfected with the HAMP promoter/luciferase construct, with TK renilla as 
control. They were also co-transfected with an HJV-expressing vector alone (mock), or HJV plus 
an MT2-expressing vector: WT MT2, Y418C MT2, L235P MT2, E114K MT2, P765A MT2, 
R567A MT2, S762A MT2, or A605fs MT2. Relative luciferase activity was determined as the 
ratio of luciferase/renilla activity. Values indicate mean activity and error bars indicate the SD. P 
values were calculated using Student’s t-test. §= HAMP promoter activity significantly different 
from the activity generated by HJV alone (P<0.05), *= HAMP promoter repression significantly 
different from WT MT2 repression (P<0.05). Each transfection was done in triplicate.  
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Figure 4: Autoactivation of MT2 variants. 
HeLa (A) and Huh7 (B) cells were transiently transfected with HJV-expressing vector alone 
(mock), HJV and either WT, or Y418C, L235P, P765A, E114K, R567A, S762A mutant MT2-
FLAG. HeLa cells were also transfected with the A605fs mutant. Whole cell extracts and 
concentrated media were loaded onto 10% and 12% SDS PAGE, respectively, transferred onto 
the membrane, and hybridized with a monoclonal anti-FLAG primary antibody for MT2 
detection. Loading controls in cell lysates were revealed by anti-actin antibodies. 
The scale shows the molecular mass in kiloDaltons. CL= cell lysates, CM= concentrated media, 
SP=serine protease domain. Arrows indicate full length or A605fs MT2. 
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Figure 5: The four missense IRIDA mutants are not transactivated by WT MT2. 
Huh7 cells were transfected with an HJV expressing vector. They were also transfected with two 
additional plasmids, one being either the empty vector or WT MT2-V5, and the other a mutated 
MT2-FLAG. Cell lysates (CL) and concentrated media (CM) were loaded onto 10% or 12% SDS 
PAGE respectively. Membranes were probed with anti-FLAG antibodies for the detection of 
MT2 mutants, and with anti-V5 antibodies for the detection of WT MT2-V5. 
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Figure 6: The medium from cells transfected with IRIDA mutants was proteolytically inactive. 
HeLa cells were transfected with HJV and MT2-expressing constructs. Activity was assayed at 
37°C, for concentrated medium (15 μg of proteins) from transfected HeLa cells, by monitoring 
the release of p-nitroanilide from the chromogenic substrate N-(tert-butoxycarbonyl)-Gln-Ala-
Arg-p-nitroanilide at a wavelength of 405 nm, for up to 20 minutes.  
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Table 1:  TMPRSS6 mutations and biological parameters of IRIDA patients 
 
 
Hematological parameters and parameters of iron status before (at diagnosis) or after (current 
data) iron treatment, and TMPRSS6 genotypes in the 5 patients from 3 families.  
 
Hb= Hemoglobin concentration, reference range: 13.5-17.5 (males), 12.5-15.5 (females). MCV= 
Mean Cellular Volume, reference range: 80-99 fL. Hepcidin concentration, reference range: 29-
254 (males), 16-288 (females) (Ganz, et al., 2008). Ferritin concentration, reference range: 30-
300 (males), 20-200 (females). TSA = Transferrin Saturation, reference range: 20–40% (males), 
15–35% (females). 
 
 
 
 
 
 
 
 Data at diagnosis Current data 
family TMPRSS6 
genotype    
amino acid 
change  
age  
(year) 
Hb  
(g/dL) 
MCV 
(fL) 
Age 
(year) 
serum 
hepcidin 
(ng/mL) 
ferritin 
(μg/l) 
TSAT 
% 
Hb 
(g/dL) 
MCV 
(fL) 
A c.[1813 delG]; 
   [1813 delG] 
p.[A605PfsX8]; 
   [A605PfsX8] 
15  
1  
7.3 
7.4 
54 
51 
25  
17  
4288 
ND 
230 
66 
4 
6 
12 
12 
64 
71 
B c.[1253A>G]; 
   [704 T>C]       
p.[L235P ]; 
   [Y418C] 
4  
0.5  
7.7 
9 
 11  
8  
62 
81 
90 
115 
5 
3 
10.5 
9.6 
64 
70 
C c.[340 G>A]; 
   [2293 C>G]     
p.[E114K]; 
   [P765A] 
3 10.2 61 7  59 20 4 10.8 71 
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Table 2:  Functional studies of MT2 mutations published in the literature 
 
Autocleavage 
 
 
Repression of HJV-induced HAMP 
promoter activity 
MT2 Mutation 
 ≠ between mock 
and MT2 mutant 
≠ between WT 
and mutant MT2 
Reference 
 
A118D  No Yes Yes (Ramsay, et al., 2009b) 
P686fs No Yes Yes (Ramsay, et al., 2009b) 
I212T Weak Yes Yes (De Falco, et al., 2010) 
R271Q Yes Yes No (De Falco, et al., 2010) 
G442R Weak Yes Yes (Silvestri, et al., 2009) 
D521N, E522K No Yes Yes (Silvestri, et al., 2009) 
MT2MASK ND No Yes (Silvestri, et al., 2008) 
Y141C No Yes Yes (Altamura, et al., 2010) 
R774C No Yes Yes (Silvestri, et al., 2008) 
Y418C No Yes Yes This paper 
L235P No Yes Yes This paper 
E114K No Yes Yes This paper 
P765A Weak Yes No This paper 
A605fs No Weak Yes This paper 
 
 
Summary of the results obtained for autocleavage of MT2 and HAMP repression in the luciferase 
assay, from different papers describing MT2 mutations, and from this paper. ND = Not 
Determined 
 
 
